Dr. Davis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
The Usona Institute
2780 Woods Hollow Rd
Fitchburg, WI 53711Phone+1 608-277-2514Fax+1 888-202-1492
Summary
- I am a board-certified psychiatrist who completed the Medical Scientist Training Program (M.D./Ph.D.) at Case Western Reserve University, receiving a Ph.D. in Pharmacology. I completed residency training in Psychiatry at the UCLA Semel Institute of Neuroscience and Human Behavior, where I was chief resident from 2011-2012. I then completed the Advanced Fellowship Program in Mental Illness Research and Treatment at the West Los Angeles VA Medical Center; as part of this fellowship, I designed and conducted clinical and translational research on novel therapeutics for schizophrenia. After 1-2 years as junior faculty at Baylor College of Medicine and the Michael E. DeBakey VA Medical Center, I transitioned to the Division of Psychiatry at the Food and Drug Administration, where I was a primary clinical reviewer and then a clinical team leader. After ~6.5 years at the FDA, I left the Agency to accept a Chief Medical Officer position at the Usona Institute, where I currently work on developing psychedelic drugs for the treatment of major depressive disorder.
Education & Training
Greater Los Angeles HCSPost-Doctoral Fellowship, 2012 - 2014
UCLA David Geffen School of Medicine/UCLA Medical CenterChief Residency, Psychiatry, 2011 - 2012- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 2008 - 2012
Case Western Reserve University School of MedicineClass of 2008, M.D.
Case Western Reserve UniversityPh.D., Pharmacology, 2002 - 2006
Iowa State UniversityB.S., Biochemistry, 1999
Certifications & Licensure
MD State Medical License 2016 - 2026
CA State Medical License 2009 - 2025
NY State Medical License 2021 - 2023- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- Friends Travel Grant The Friends of the Semel Institute for Neuroscience and Human Behavior at UCLA, 2014
- New Investigator Award American Society of Clinical Psychopharmacology, 2014
- Schizophrenia Research Fellowship Award American Psychiatric Foundation, 2013
- Join now to see all
Clinical Trials
- Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia? Start of enrollment: 2011 Apr 01
- Pharmacological Approach to Improve the Outcome of Social Cognition Training Start of enrollment: 2012 Jan 01
- N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia Start of enrollment: 2013 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.William P Horan, Gary Sachs, Dawn I Velligan, Michael Davis, Richard S E Keefe
Innovations in Clinical Neuroscience. 2024-03-01 - Innovative Technologies in CNS Trials: Promises and Pitfalls for Recruitment, Retention, and Representativeness.Jacqueline Lutz, Abhishek Pratap, Eric J Lenze, Durga Bestha, Jessica M Lipschitz
Innovations in Clinical Neuroscience. 2023-09-01 - 12 citationsEffect of Paroxetine or Quetiapine Combined With Oxycodone vs Oxycodone Alone on Ventilation During Hypercapnia: A Randomized Clinical Trial.Jeffry Florian, Rutger van der Schrier, Victoria Gershuny, Michael C Davis, Celine Wang
JAMA. 2022-10-11
Journal Articles
- Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patientsDavis MC, Fuller MA, Strauss ME, Konicki PE, Jaskiw GE, Acta Psychiatrica Scandinavica, 1/1/2014
- Psychopharmacology of the Negative Symptoms: Current Status and Prospects for ProgressDavis MC, Horan WP, Marder SR, European Neuropsychopharmacology, 1/1/2014
- New-onset extrapyramidal symptoms following oxcarbazepine discontinuation in a child receiving risperidoneKruse JL & Davis MC, Journal of Child and Adolescent Psychopharmacology, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Can Oxytocin Enhance Learning During Social Cognitive Skills Training in Schizophrenia?Davis MC, Green MF, Lee J, Horan WP, Wynn JK, Marder SR, Society of Biological Psychiatry Annual Meeting, Biological Psychiatry, 5/8/2014
- Can Oxytocin Enhance Learning During Social Cognitive Skills Training in Schizophrenia?Davis MC, Green MF, Lee J, Horan WP, Wynn JK, Marder SR, American College of Neuropsychopharmacology Annual Meeting, 12/8/2013
- Psychiatric Manifestations and Management of Anti-NMDA Receptor Encephalitis.Kruse JL, Jeffrey JK, Davis MC, Brooks JO III, Academy of Psychosomatic Medicine Annual Meeting, 11/15/2013
- Join now to see all
Lectures
- Effects of single dose intranasal oxytocin on social cognition in schizophrenia.San Francisco, CA - 1/1/2013
- N-Acetylcysteine in PsychiatryUCLA Semel Institute of Neuroscience and Human Behavior
- Oxytocin and Social Cognition in SchizophreniaWest Los Angeles VA Medical Center
- Join now to see all
Press Mentions
Review the Article, “Facing Our Fears.”January 3rd, 2021
Grant Support
- Advanced Fellowship in Mental Illness Research and TreatmentVA Mental Illness Research, Education, and Clinical Center2012–2014
- Pala Pilot GrantVISN 22 Mental Illness Research, Education, and Clinical Center2011–2012
- Medical Scientist Training ProgramNIH2000–2008
- Hematology Training GrantNIH2004–2006
- Howard Hughes Medical Institute Research AssistantshipHHMI1998–1999
- Signal Transduction Training Group InternshipNSF1998–1999
Committees
- Resident representative, Outpatient Practice Council 2011 - 2012
- Psychiatry resident representative, Graduate Medical Education Committee 2011 - 2012
- Cutting Edge Journal Club Coordinator; Recruitment Committee Member; Resident Handbook Chairman; Resident Website Administrator; President, Psychiatry Residency Council 2009 - 2012
- Resident representative, Psychiatry Residency Oversight Committee 2008 - 2012
- Monthly meeting chairperson, Medical Scientist Training Program 2004 - 2005
- Graduate Student Senate representative; Summer Undergraduate Research Program chairperson; Social chairperson; discussion group steering committee, Department of Pharmacology Graduate Student Organization 2003 - 2006
- Student representative, Student Health Advisory Committee 1998 - 1999
Research History
- Research FellowDevelopment of novel therapeutics for treatment-resistant symptoms of schizophrenia2012 - 2014
- Psychiatry Residency Research TrackPharmacological enhancement of social cognition in individuals with schizophrenia2008 - 2012
- Medical student research`Analysis of the frequency, causes, and outcomes of clozapine discontinuation2007 - 2007
- Ph.D. thesis researchGeneration and regulation of pro-apoptotic calcium signals in T cells2002 - 2006
- Research assistantRegulation of calcitonin gene-related peptide during migraines2000 - 2000
- Undergraduate research; Research assistantRole of glucocorticoids in multi-drug resistance of human leukemic lymphocytes1999 - 2000
- Undergraduate researchAnalysis of glutamate release from astrocytes using fluorescence microscopy and fiber optics/laser instrumentation1998 - 1998
- Undergraduate researchInvestigation of the role of phospholipase A2 in neurotransmitter-induced release of calcium from astrocytes1998 - 1998
- Undergraduate researchLipid analysis of pork samples for National Pork Producers Council-sponsored project1997 - 1997
- Undergraduate researchDeveloped PERL scripts and web-based interface for genetics bioinformatics tools1997 - 1997
Professional Memberships
- Member
- American Society of Clinical PsychopharmacologyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
